A new computational study published in Discover Chemistry by Zara Javaid, Hafiza Salaha Mahrosh, Saad Serfraz and Amer Jamil of the University of Agriculture, Faisalabad, set out to close this gap by screening plant-derived molecules against two of the virus’s most strategically important proteins. The team assembled a library of 1,000 phytochemicals with documented antiviral, antioxidant or anticancer activity, drawn from the IMPPAT database, Dr. Duke’s Phytochemical and Ethnobotanical Database and published literature, and docked them against glycoprotein 42, the envelope protein that mediates viral entry into B cells, and Epstein–Barr nuclear antigen 1, the latency protein that maintains and partitions the viral episome during cell division.

The choice of targets reflects a deliberate dual strategy. Glycoprotein 42 is a surface-exposed glycoprotein that binds HLA class II molecules and works alongside the gH and gL glycoproteins to drive membrane fusion, making it an accessible point of attack during the earliest stages of infection. Peptide inhibitors directed at this protein have already shown nanomolar antiviral activity in prior work, validating its therapeutic potential. EBNA1, by contrast, is a 641-amino-acid nuclear protein expressed in every EBV-linked cancer and is essential for viral genome replication and persistence; no FDA-approved inhibitor of it exists. By targeting both an entry factor and a latency factor simultaneously, the researchers aimed to identify compounds with combined antiviral and antineoplastic potential, an approach that distinguishes their workflow from earlier studies focused on single targets or synthetic libraries.

The docking screen, performed with the AutoDock Vina engine inside PyRx, produced clear front-runners. Against glycoprotein 42, the steroidal saponin hecogenin achieved the strongest binding energy of −8.9 kcal/mol, forming a hydrogen bond with glutamine 92 and hydrophobic contacts with tyrosine 167, phenylalanine 129 and histidine 191. Other strong performers included baicalin, islandicin, swertisin, hortensin, pedalitin, epigallocatechin, pinoresinol, hesperetin and verbenalin. Against EBNA1, the plant sterol cyclobranol led with a score of −8.2 kcal/mol, anchoring itself in a hydrophobic pocket through contacts with phenylalanine 508, tyrosine 510 and leucine 539. Notably, acyclovir, used as a comparator control, scored only −4.7 kcal/mol against glycoprotein 42 and −4.9 kcal/mol against EBNA1, placing it last among the screened ligands and suggesting that the top phytochemicals bind both viral proteins more favorably than the standard clinical antiviral.

The authors took care to validate their docking protocol. The native co-crystallized ligand of EBNA1 was extracted and redocked under identical parameters, reproducing the experimental binding geometry with a heavy-atom root-mean-square deviation of 0.958 angstroms, well within the accepted threshold of 2 angstroms. Redocking validation was not possible for glycoprotein 42, which was solved in its unbound form without a co-crystallized ligand, a structural limitation the team acknowledged openly. Docking scores, they stressed, are estimates of binding compatibility rather than predictions of biological potency, and experimental confirmation remains essential.

From the top-ranked compounds, the researchers applied Lipinski’s rule of five as an initial filter for oral drug-likeness. Hesperetin, hecogenin, islandicin, hortensin, pedalitin, pinoresinol and verbenalin passed with no violations, while brassicasterol, swertisin, caftaric acid and epigallocatechin each violated a single criterion. Compounds with more than two violations, including cyclobranol, stigmasterol, baicalin and taraxerol, were excluded. The authors noted that natural products often carry greater structural complexity than synthetic drugs, so broader physicochemical descriptors were reserved for the later pharmacokinetic assessment rather than used as absolute exclusion criteria at this early stage.

The study then moved into network pharmacology, linking the surviving compounds to their predicted human gene targets through SwissTargetPrediction and the STITCH database, and cross-referencing these against EBV- and EBV-cancer-associated genes retrieved from GeneCards and DisGeNET. The intersection yielded 132 shared targets, which were mapped into a protein–protein interaction network using STRING and visualized in Cytoscape. The network contained 132 nodes and 827 edges, and degree-based analysis with the CytoHubba plugin identified ten hub genes: TP53, HSP90AA1, AKT1, SRC, BCL2, EGFR, TNF, ESR1, ERBB2 and PIK3CA. Gene Ontology and KEGG enrichment showed these genes clustered in apoptosis regulation, kinase signaling, the PI3K-Akt pathway and viral oncogenesis pathways, including EBV infection itself and Kaposi’s sarcoma-associated herpesvirus infection, consistent with the virus’s known strategy of suppressing host cell death and hijacking kinase cascades to maintain latency and drive proliferation.

When the eight drug-like phytochemicals were docked against the EBV-associated cancer proteins, hecogenin again dominated, achieving the best score against nine of the ten targets. Its strongest interaction was with the TP53 DNA-binding domain at −10.9 kcal/mol, stabilized by hydrogen bonds with glycine 112, phenylalanine 113 and serine 116, followed by −10.6 kcal/mol against PIK3CA and −10.4 kcal/mol against SRC. Pinoresinol, swertisin and hesperetin also performed well. To test whether the hecogenin–TP53 interaction could survive realistic physical conditions, the team ran a 200-nanosecond molecular dynamics simulation in GROMACS using the CHARMM36 force field on an NVIDIA H100 GPU. The protein backbone remained stable throughout, with RMSD values of 2.0 to 2.8 angstroms and a nearly constant radius of gyration, while the ligand’s internal geometry barely changed, with a ligand RMSF of only about 0.35 angstroms. The ligand did, however, wander considerably relative to its docked pose, and hydrogen bond analysis revealed mostly transient polar contacts, indicating that the complex is held together primarily by hydrophobic and van der Waals forces in a dynamic rather than rigid binding mode.

Predicted pharmacokinetics added further support. ADMET profiling with SwissADME and pkCSM indicated no AMES toxicity, hepatotoxicity or skin sensitization for the lead compounds, and both hecogenin and pinoresinol were predicted to cross the blood–brain barrier and show high gastrointestinal absorption, placing them in the favorable yolk region of the Boiled Egg plot. As P-glycoprotein substrates, both would be actively pumped out of the central nervous system, limiting CNS exposure but potentially improving peripheral safety. The authors were candid about the caveats: hecogenin’s broad affinity across structurally unrelated proteins raises the possibility of promiscuous, hydrophobicity-driven binding rather than genuine multitarget specificity, and although the compound triggered no PAINS alerts, orthogonal assays such as surface plasmon resonance and thermal shift experiments will be needed to separate true polypharmacology from assay interference.

Hecogenin itself is a steroidal saponin from Agave sisalana with a prior record of anti-inflammatory, antimicrobial and antitumor research, while pinoresinol is a lignan from sesame seeds and olive oil, and hesperetin and swertisin are flavonoids with documented anticancer and immunomodulatory properties. The study’s real contribution may lie as much in its framework as in its lead compound: an integrated pipeline that couples large-scale docking, network pharmacology, enrichment analysis, ADMET prediction and molecular dynamics into a reproducible workflow for discovering mechanism-based antiviral agents from natural sources. The researchers emphasize that all findings are computational and hypothesis-generating, and that in vitro and in vivo validation is required before hecogenin or its counterparts can be considered genuine therapeutic candidates against EBV infection and the cancers it leaves in its wake.

Subject of Research: Computational screening of phytochemicals as multitarget inhibitors of Epstein–Barr virus infection and EBV-associated malignancies

Article Title: Network pharmacology and molecular docking-based screening of phytochemicals as multitarget inhibitors of Epstein–Barr virus infection and associated malignancies

Article References: Javaid, Z., Mahrosh, H. S., Serfraz, S., & Jamil, A. (2026). Network pharmacology and molecular docking-based screening of phytochemicals as multitarget inhibitors of Epstein–Barr virus infection and associated malignancies. Discover Chemistry, 3(1), Article 577. https://doi.org/10.1007/s44371-026-01029-1

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01029-1

Keywords: Epstein–Barr virus, network pharmacology, molecular docking, hecogenin, phytochemicals, EBNA1, glycoprotein 42, molecular dynamics simulation, ADMET, oncogenic viruses, drug discovery, TP53

The Notch pathway is one of the most evolutionarily conserved signaling systems in multicellular organisms. In mammals it comprises four transmembrane receptors, NOTCH1 through NOTCH4, and five membrane-bound ligands of the Delta-like and Jagged families. Signaling is unusual in that it does not rely on a second-messenger cascade: when a ligand on a neighboring cell engages a Notch receptor, the receptor undergoes sequential cleavage, first by ADAM-family metalloproteinases and then by the γ-secretase complex. This releases the Notch intracellular domain (NICD), which translocates to the nucleus and binds the DNA-associated transcription factor CSL, together with the coactivator Mastermind-like (MAML), to switch on target genes. Foremost among these are the Hairy and Enhancer of Split (HES) and HEY family transcriptional repressors, which in turn control genes governing proliferation, differentiation, and survival.

Because Notch sits at the helm of decisions about when cells divide, when they differentiate, and when they die, even modest dysregulation can be dangerous. The review emphasizes that abnormal Notch activity has been implicated in cell proliferation, resistance to apoptosis, maintenance of stem-like cell populations, epithelial–mesenchymal transition (EMT), and immune evasion. In normal tissue these processes are carefully balanced; in cancer they are the engine of tumor growth and spread. The authors’ central thesis is that oncoviruses exploit this pathway deliberately, co-opting its transcriptional output to create a cellular environment favorable to viral persistence and, ultimately, malignant transformation.

HPV provides one of the clearest examples. The viral oncoproteins E6 and E7, which drive degradation of the tumor suppressors p53 and pRB, also interact with Notch signaling in ways that shift the pathway’s effects. Notch signaling in HPV-infected keratinocytes can cooperate with viral gene expression to sustain proliferation and block terminal differentiation—the very process the virus must arrest to complete its life cycle. The review notes that HPV-positive lesions show altered expression of Notch receptors and ligands, and that the interplay between E6/E7 and NICD-dependent transcription blurs the line between the productive viral life cycle and neoplastic progression, particularly in cervical carcinogenesis.

HTLV-1, the causative agent of adult T-cell leukemia/lymphoma (ATLL), takes a different route. Its trans-activator protein Tax is a potent manipulator of host transcription factors, and the review describes how Tax-driven activation of NF-κB and AP-1 converges with Notch signaling to keep infected T cells in a proliferative, apoptosis-resistant state. The HTLV-1 basic leucine zipper factor (HBZ), expressed from the antisense strand, further entrenches this program, supporting the survival and expansion of leukemic clones. The same virus is also associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), underscoring that Notch manipulation has consequences beyond cancer.

Among the herpesviruses, EBV and KSHV display especially intricate relationships with Notch. EBV latency proteins, including the Epstein–Barr nuclear antigens (EBNAs) and latent membrane proteins (LMPs), modulate Notch receptor processing and downstream transcription; LMP1 and LMP2A signaling intersects with NICD-mediated gene activation in nasopharyngeal carcinoma and EBV-associated lymphoid malignancies. KSHV, the etiologic agent of Kaposi’s sarcoma, deploys its own arsenal: the latency-associated nuclear antigen (LANA), the viral FLICE-inhibitory protein (vFLIP), and the viral G protein-coupled receptor (vGPCR) each contribute to Notch pathway activation, fostering the angiogenesis, inflammation, and cell survival that characterize the tumor. The replication and transcription activator (RTA), which controls the viral lytic switch, adds a further layer of regulation linking viral life cycle dynamics to host signaling.

The hepatitis viruses illustrate that even viruses not conventionally classed as DNA-tumor viruses participate in this crosstalk. HBV’s X protein (HBx) promotes Notch activation in hepatocytes, contributing to the proliferative and survival signals that underlie hepatocellular carcinoma, while HCV proteins engage the pathway in ways that reinforce chronic inflammation and fibrogenic progression toward malignancy. In both cases, the review suggests that Notch dysregulation acts as a bridge between chronic viral injury and the molecular events of carcinogenesis, potentially offering biomarkers that distinguish progressing lesions from indolent disease.

A recurring theme across all six viruses is context dependence. Notch can behave as an oncogene in some tissues and as a tumor suppressor in others, and the review stresses that the outcome of viral manipulation depends on cell type, the differentiation state of the infected cell, and which receptors and ligands are expressed. Additional layers of control—including microRNAs, long non-coding RNAs, the E3 ubiquitin ligase FBXW7 that targets NICD for degradation, and fringe glycosyltransferases such as Manic Fringe that modify ligand–receptor affinity—determine where the signaling dial sits. Viruses appear to nudge these layers simultaneously, producing a coherent pro-tumor transcriptional state rather than a single wholesale switch.

The therapeutic implications are significant. γ-secretase inhibitors (GSIs), originally developed for Alzheimer’s disease and already tested in Notch-driven T-cell leukemias, emerge as a class of compounds that could, in principle, sever the viral exploitation of the pathway. The review also points toward Notch-related biomarkers for early detection and risk stratification in virus-associated cancers, and toward combination strategies in which antiviral therapy is paired with pathway-targeted agents. However, the authors caution that Notch’s dual roles and its importance in normal stem cell maintenance demand careful dosing and tissue-specific approaches.

The review closes by flagging the field’s unresolved questions: the precise order in which viral proteins and Notch activation act during multi-step carcinogenesis, the contribution of Notch to immune evasion in virally infected tissue, and whether Notch signatures can reliably predict transformation in premalignant lesions. What is already clear, the authors conclude, is that deeper mechanistic understanding of virus–Notch crosstalk could reshape basic research on viral carcinogenesis, yield diagnostic biomarkers, and guide the next generation of targeted antiviral and anti-cancer therapies. As the list of virus-associated malignancies continues to grow, the Notch pathway looks increasingly like common ground on which these diverse pathogens meet.

Subject of Research: Dysregulation of the Notch signaling pathway by human oncogenic viruses in carcinogenesis

Article Title: Oncogenic human viruses and notch signaling: a focus on key dysregulation within the NOTCH pathway

Article References: Oncogenic human viruses and notch signaling: a focus on key dysregulation within the NOTCH pathway. (n.d.). https://doi.org/10.1186/s12985-026-03324-w

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03324-w

Keywords: Notch signaling, oncogenic viruses, HPV, HTLV-1, EBV, KSHV, HBV, HCV, carcinogenesis, NICD, gamma-secretase inhibitors, EMT

Chaperone-mediated autophagy, or CMA, is distinct from the better-known bulk-recycling form of autophagy. Instead of engulfing entire cellular structures in membrane-bound vesicles, CMA operates one protein at a time. Cytoplasmic proteins carrying a specific pentapeptide recognition motif are bound by the chaperone HSC70 and delivered to the lysosomal membrane, where LAMP2A acts as the receptor. The substrate protein then unfolds and threads through a multimeric channel formed by LAMP2A molecules into the lysosomal lumen, where it is degraded. Because this pathway can selectively remove transcription factors, metabolic enzymes and signaling proteins, it has long been implicated in cancer progression, immune regulation and aging, yet how pathogens manipulate it has remained poorly understood.

The new work began with a proteomic search for proteins that associate with TRIM32, a member of the tripartite motif family of E3 ligases, during KSHV infection. Using mass spectrometry on purified TRIM32 complexes from infected cells, the researchers found that TRIM32 interacted prominently with components of the CMA machinery, including HSC70, HSP90 and LAMP2A itself. Gene ontology analysis of the interactors confirmed enrichment in chaperone-mediated autophagy and innate immune pathways. When cells were stimulated with double-stranded DNA, a molecular stand-in for viral DNA sensing, TRIM32 formed visible cytoplasmic bodies that co-localized with LAMP2A and other CMA components, and the physical interaction between TRIM32 and LAMP2A could be recapitulated with purified recombinant proteins in vitro.

The pivotal discovery concerned a post-translational modification known as SUMOylation, in which small ubiquitin-like modifier proteins, chiefly SUMO2 and SUMO3, are covalently attached to lysine residues on target proteins. SUMOylation is reversible and frequently alters a protein’s localization, interaction partners or stability, and it has well-documented roles in both viral infection and tumorigenesis. The team showed that TRIM32 acts as a SUMO E3 ligase for LAMP2A, conjugating SUMO2/3 to three specific lysines: K104, K132 and K289. Detailed mapping experiments revealed that K289 and K104 serve as primary sites for SUMO2 attachment, while a SUMO-interacting motif on LAMP2A, SIM1, facilitates SUMO3 modification at K132. The RING domain of TRIM32 proved essential for this modification.

What makes this modification so consequential is where it sends LAMP2A. Although LAMP2A is classically viewed as a lysosomal membrane receptor, the study found that SUMOylated LAMP2A accumulates in the nucleus during viral infection. This nuclear translocation of LAMP2A, driven by TRIM32-dependent SUMOylation, activates the CMA program, allowing the infected cell to selectively degrade a distinct set of client proteins. Among the consequences documented in the paper is the suppression of viral reactivation and inflammation: by keeping the lytic program damped down, the virus preserves latency, its long-term persistence strategy, while the altered cellular environment simultaneously favors tumor growth and the formation of new blood vessels, a process called angiogenesis.

Using KSHV as a model system, the researchers demonstrated in animal models that TRIM32-induced SUMOylation of LAMP2A promotes tumor growth and angiogenesis in vivo. When LAMP2A was depleted from KSHV-transformed cells, TRIM32’s ability to drive colony formation and xenograft expansion collapsed. Reconstituting the cells with wild-type LAMP2A restored tumorigenesis, but reconstitution with SUMOylation-defective mutants, in which the key lysines were changed to arginine, failed to do so. Immunohistochemical staining of the resulting tumors showed corresponding changes in markers of proliferation, endothelial content and viral lytic reactivation, tying the molecular modification directly to pathological outcomes.

Crucially, the mechanism appears not to be a quirk of KSHV alone. In tumor tissues from patients, the team found that TRIM32 expression positively correlates with LAMP2A in cancers associated with KSHV, Epstein–Barr virus and human papillomavirus, the viruses behind Kaposi’s sarcoma, nasopharyngeal carcinoma and cervical cancer, respectively. The correlation was stratified by the abundance of viral latent antigens such as LANA, EBNA1 and E6, suggesting that the burden of latent viral infection tracks with activation of this CMA-regulating axis. A pan-cancer analysis using the GEPIA database further showed coordinated TRIM32 and LAMP2A expression across a range of tumor types, hinting that the pathway may extend beyond classic tumor viruses.

Perhaps the most translationally exciting aspect of the study is the development of peptide inhibitors that target the SUMOylated form of LAMP2A. Derived from LAMP2A sequences, the peptides P3 and P7 were designed to disrupt the SUMOylation-dependent nuclear localization and function of the receptor. In cell culture, the peptides suppressed colony formation by KSHV-, EBV- and HPV-infected cancer cells at concentrations that showed minimal cytotoxicity toward uninfected cells. In mouse xenograft models, including both subcutaneous and intraperitoneal tumor systems, treatment with the peptides reduced tumor progression and angiogenesis. The antitumor effect depended on intact LAMP2A and SUMO2: the peptides lost efficacy in cells lacking LAMP2A or with SUMO2 knocked out, and in cells reconstituted with SUMOylation-site mutants, confirming that the drugs act precisely on the pathway the team had dissected.

The work also clarifies a long-standing puzzle about how oncogenic viruses balance two competing needs. Reactivating into the lytic cycle produces new viral particles but exposes the infection to immune detection and inflammatory stress, whereas permanent latency forgoes transmission. By activating CMA through SUMOylated LAMP2A, the virus appears to buy itself a stable middle ground: lytic genes stay quiet, inflammatory signaling is blunted, and the host cell survives long enough to accumulate the mutations and vascular support that a tumor requires. Earlier studies had shown that CMA is required for tumor growth and that LAMP2A is overexpressed in several malignancies, but the viral trigger and the specific enzymatic machinery, TRIM32 acting on defined lysines, had not previously been connected.

For patients with virus-associated cancers, the implications are significant. Current treatments for Kaposi’s sarcoma and related malignancies often rely on broad chemotherapy or immune modulation, and options specifically targeting the virus–host interface remain limited. A receptor like LAMP2A, positioned at the convergence of viral persistence and tumor maintenance, offers a single point of intervention with dual antiviral and antitumor potential. The peptide approach also demonstrates that blocking a specific post-translational modification, rather than the entire autophagy pathway, can achieve therapeutic selectivity, an important consideration given CMA’s normal roles in neurons, liver and immune cells. The authors have filed a provisional patent on the compositions and methods, and while peptide drugs face delivery and stability hurdles before clinical use, the study establishes LAMP2A SUMOylation as a promising and mechanistically well-defined target. As oncogenic viruses continue to account for a substantial share of cancers worldwide, understanding and interrupting the molecular hijacking they perform may prove one of the most consequential strategies in virology-driven cancer therapy.

Subject of Research: How oncogenic viral infection drives LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis

Article Title: Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis

Article References: Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis. (n.d.). https://doi.org/10.1038/s41564-026-02476-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02476-3

Keywords: KSHV, LAMP2A, TRIM32, SUMOylation, chaperone-mediated autophagy, oncogenic viruses, tumorigenesis, angiogenesis, Epstein-Barr virus, human papillomavirus, virus-host interactions, peptide inhibitors